In this free webinar, learn about advanced orthotopic engraftment techniques to develop models of spontaneous metastases. Attendees will learn about the use of whole body and focal radiation to mimic clinical scenarios, to support both in vivo and in vitro studies. The featured speakers will discuss reducing variability between in vitro and in vivo studies by employing matched pairs of patient-derived xenograft (PDX) models and the three-dimensional cell cultures derived from them. Attendees will learn about emerging approaches to humanized PDX models to recapitulate the human tumor microenvironment and evaluate immune response.
TORONTO, Dec. 2, 2022 /PRNewswire-PRWeb/ -- To develop the next generation of targeted cancer therapies, researchers need cancer models that can stand in as true proxies for human disease. Traditional research models commonly used in commercial applications have a place in screening and can provide directional information about potential therapeutic responses. However, they do not replicate the heterogenous biology and complex network of dysregulated pathways that characterize real-life human tumors. In fact, most models used in preclinical drug development fail to address the importance of tumor microenvironment, despite its well-established role in druggability and immune response. Translational research in oncology can greatly benefit from improvements to these models.
Innovative approaches to model development can address many shortcomings of legacy models. What's more, both in vitro and in vivo test systems can now be customized to account for the myriad of clinical scenarios (prior treatment, radiotherapy, acquired resistance, metastases) that may ultimately determine clinical response to a given experimental therapy.
Translational research success is largely dependent upon selecting — or sometimes custom-developing — the most appropriate preclinical model to assess a candidate's therapeutic response. During this webinar, the featured speakers will review current literature on cell culture, organoids/spheroids and various types of in vivo mouse models and discuss emerging techniques for developing more clinically relevant models of cancer.
Register to learn about the innovations in preclinical model development for translational research in oncology.
Join experts from Certis Oncology Solutions, Jonathan Nakashima, PhD, Chief Scientific Officer; Jantzen Sperry, PhD, Senior Director, Scientific Operations; and Rajeev Shrimali, PhD, Senior Director, Immuno-Oncology R&D, for the live webinar on Wednesday, December 14, 2022, at 2pm EST (11am PST).
For more information, or to register for this event, visit Translational Research in Oncology — Innovations in Model Development.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article